Richard Alexander Collins Sells 3,948 Shares of DexCom (NASDAQ:DXCM) Stock

DexCom, Inc. (NASDAQ:DXCM) Director Richard Alexander Collins sold 3,948 shares of the stock in a transaction on Monday, November 10th. The stock was sold at an average price of $55.17, for a total value of $217,811.16. Following the completion of the transaction, the director owned 37,994 shares in the company, valued at approximately $2,096,128.98. This represents a 9.41% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

DexCom Stock Down 0.3%

Shares of DexCom stock traded down $0.16 during trading hours on Monday, reaching $54.84. The company’s stock had a trading volume of 8,862,721 shares, compared to its average volume of 4,532,221. The company has a market capitalization of $21.39 billion, a P/E ratio of 38.08, a P/E/G ratio of 1.43 and a beta of 1.40. The stock’s fifty day simple moving average is $68.83 and its two-hundred day simple moving average is $77.61. DexCom, Inc. has a one year low of $54.11 and a one year high of $93.25. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.35 and a current ratio of 1.52.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, October 30th. The medical device company reported $0.61 earnings per share for the quarter, topping analysts’ consensus estimates of $0.57 by $0.04. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The company had revenue of $1.21 billion for the quarter, compared to analyst estimates of $1.18 billion. During the same quarter in the prior year, the business posted $0.45 EPS. The firm’s revenue was up 21.6% compared to the same quarter last year. DexCom has set its FY 2025 guidance at EPS. On average, research analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the company. TD Cowen dropped their target price on DexCom from $100.00 to $84.00 and set a “buy” rating on the stock in a report on Friday, October 31st. Stifel Nicolaus started coverage on DexCom in a research note on Tuesday, October 21st. They set a “buy” rating and a $85.00 price objective on the stock. Robert W. Baird set a $82.00 price objective on shares of DexCom in a report on Friday, October 31st. Argus lowered their target price on shares of DexCom from $100.00 to $90.00 and set a “buy” rating for the company in a report on Friday. Finally, The Goldman Sachs Group dropped their price target on shares of DexCom from $104.00 to $89.00 and set a “buy” rating on the stock in a research report on Wednesday, October 1st. Three equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $87.62.

Hedge Funds Weigh In On DexCom

Institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its position in DexCom by 2.3% in the third quarter. Vanguard Group Inc. now owns 49,456,043 shares of the medical device company’s stock worth $3,327,897,000 after acquiring an additional 1,133,638 shares during the period. Jennison Associates LLC raised its holdings in shares of DexCom by 9.4% in the 2nd quarter. Jennison Associates LLC now owns 11,517,546 shares of the medical device company’s stock worth $1,005,367,000 after purchasing an additional 994,300 shares during the period. Geode Capital Management LLC lifted its stake in DexCom by 3.4% in the second quarter. Geode Capital Management LLC now owns 10,766,356 shares of the medical device company’s stock valued at $936,100,000 after purchasing an additional 358,617 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in DexCom by 22.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 10,123,525 shares of the medical device company’s stock valued at $691,336,000 after purchasing an additional 1,868,241 shares during the period. Finally, Nuveen LLC purchased a new stake in DexCom in the first quarter worth $554,893,000. Institutional investors own 97.75% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.